BCTX (BriaCell Therapeutics) Total Liabilities : $6.14 Mil (As of Jan. 2025)

View and export this data going back to 2023. Start your Free Trial

What is BriaCell Therapeutics Total Liabilities?

BriaCell Therapeutics's Total Liabilities for the quarter that ended in Jan. 2025 was $6.14 Mil.

BriaCell Therapeutics's quarterly Total Liabilities declined from Jul. 2024 ($8.56 Mil) to Oct. 2024 ($6.70 Mil) and declined from Oct. 2024 ($6.70 Mil) to Jan. 2025 ($6.14 Mil).

BriaCell Therapeutics's annual Total Liabilities declined from Jul. 2022 ($32.25 Mil) to Jul. 2023 ($30.94 Mil) and declined from Jul. 2023 ($30.94 Mil) to Jul. 2024 ($8.56 Mil).

BriaCell Therapeutics Total Liabilities Historical Data

The historical data trend for BriaCell Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Total Liabilities Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Total Liabilities

Get a 7-Day Free Trial

4.12

30.37

32.25

30.94

8.56

BriaCell Therapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Liabilities	Get a 7-Day Free Trial															20.55	12.44	8.56	6.70	6.14

BriaCell Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BriaCell Therapeutics's Total Liabilities for the fiscal year that ended in Jul. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.461	+	(0	+	1.096
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	8.56

Total Liabilities	=	Total Assets (A: Jul. 2024 )	-	Total Equity (A: Jul. 2024 )
	=	5.872	-	-2.685
	=	8.56

BriaCell Therapeutics's Total Liabilities for the quarter that ended in Jan. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.231	+	(0	+	0.906
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	6.14

Total Liabilities	=	Total Assets (Q: Jan. 2025 )	-	Total Equity (Q: Jan. 2025 )
	=	9.364	-	3.227
	=	6.14

BriaCell Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

8BT0:Germany BCT:Canada

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0